Issue 3/2023
Content (20 Articles)
The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4
Wenhu Chen, Liqiang Hu, Xuemei Lu, Xiaofei Wang, Changan Zhao, Chen Guo, Xiaoyan Li, Yuqin Ding, Hongguang Zhao, Dongdong Tong, Lifang Wang, Chen Huang
Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study
Lesley Stafford, Michelle Sinclair, Phyllis Butow, Janemary Hughes, Allan Park, Leslie Gilham, Allison Rose, G. Bruce Mann
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Tom Wei-Wu Chen, Wen Hsiao, Ming-Shen Dai, Ching-Hung Lin, Dwan-Ying Chang, I-Chun Chen, Ming-Yang Wang, Shu-Han Chang, Shu-Min Huang, Ann-Lii Cheng, Ko-Wen Wu, Kien Thiam Tan, Yen-Shen Lu
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
Lubna N. Chaudhary, Julie M. Jorns, Yunguang Sun, Yee Chung Cheng, Sailaja Kamaraju, John Burfeind, Mary Beth Gonyo, Amanda L. Kong, Caitlin Patten, Tina Yen, Chandler S. Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Shirng-Wern Tsaih, Anjishnu Banerjee, Yu Wang, Inna Chervoneva, Elizabeth Weil, Christopher R. Chitambar, Hallgeir Rui
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry
Yayoi Adachi, Sota Asaga, Hiraku Kumamaru, Naoko Kinugawa, Yasuaki Sagara, Naoki Niikura, Hiromitsu Jinno, Shigehira Saji, Masakazu Toi
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)
Kokoro Kobayashi, Norikazu Masuda, Toshiro Mizuno, Kayo Miura, Yutaka Tokuda, Tetsuhiro Yoshinami, Hidetoshi Kawaguchi, Shoichiro Ohtani, Toshiaki Saeki, Masakazu Toi, Masahiro Takeuchi, Yoshinori Ito
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?
M. Umit Ugurlu, Onur Bugdayci, Ahmet Akmercan, Handan Kaya, Tugba Akin Telli, Haldun Akoglu, Bahadir M. Gulluoglu
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC–MS/MS (liquid chromatography–tandem mass spectrometry) method for estrogen measurement
Mária Faltinová, Leena Vehmanen, Heli Lyytinen, Mikko Haanpää, Esa Hämäläinen, Aila Tiitinen, Carl Blomqvist, Johanna Mattson
The dynamics of HER2-low expression during breast cancer progression
Sarah Anderson, Brooke Baxter Bartow, Gene P. Siegal, Xiao Huang, Shi Wei
Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index
Anas Mohamed, Linnea T. Olsson, Joseph Geradts
Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system
Sarah Knerr, Boya Guo, Karen J. Wernli, Kathleen F. Mittendorf, Heather Spencer Feigelson, Marian J. Gilmore, Gail P. Jarvik, Tia L. Kauffman, Erin Keast, Elizabeth G. Liles, Frances L. Lynch, Kristin R. Muessig, Sonia Okuyama, David L. Veenstra, Jamilyn M. Zepp, Benjamin S. Wilfond, Beth Devine, Katrina A. B. Goddard
The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy
M. E.C. Waaijer, A. A. Lemij, A. Z. de Boer, E. Bastiaannet, F. van den Bos, M. G.M. Derks, J. R. Kroep, G. J. Liefers, J. E.A. Portielje, N. A. de Glas
Sexual health in long-term breast cancer survivors: a comparison with female population controls from the HUNT study
Solveig K. Smedsland, Kathrine F. Vandraas, Ragnhild S. Falk, Julie Horn, Randi J. Reidunsdatter, Cecilie E. Kiserud, Alv A. Dahl, Mette Brekke, Kristin V. Reinertsen
Treatments for breast cancer in men: late effects and impact on quality of life
Jorge Avila, Beth Herrick, Deanna J. Attai, José Pablo Leone
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast
Satoko Tsunokake, Erina Iwabuchi, Yasuhiro Miki, Ayako Kanai, Yoshiaki Onodera, Hironobu Sasano, Takanori Ishida, Takashi Suzuki
FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer
Chen Chen, Leiguang Ye, Jinfeng Yi, Tang Liu, Zhigao Li
Oestrogen receptor low positive breast cancer: associations with prognosis
Anette H. Skjervold, Marit Valla, Anna M. Bofin
Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases
Bo-Fang Chen, Yi-Fang Tsai, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Han-Fang Cheng, Ling-Ming Tseng, Chi-Cheng Huang
Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers
Tanu Sharma, Yuanjin Zhang, Alexandra Zigrossi, Benjamin F. Cravatt, Irida Kastrati
Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients
Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Kathrin Geiger, Stella Gaenger, Heinz Drexel, Tobias Dechow, Thomas Decker